Patents by Inventor Sheetij Dutta

Sheetij Dutta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220160855
    Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.
    Type: Application
    Filed: April 27, 2018
    Publication date: May 26, 2022
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Sheetij Dutta, Zoltan Beck, Carl Alving, Gary Matyas
  • Patent number: 11285204
    Abstract: The disclosure generally provides recombinant proteins comprising Tobamovirus capsid proteins and an immunogenic epitope of an antigen of interest. The recombinant protein can be used to assemble an array comprising a plurality of associated recombinant proteins that can enhance the immunogenicity of the epitope and induce and/or enhance an immune response to the antigen. The disclosure also provides compositions, such as vaccines, that include the recombinant protein as well as methods for inducing and/or enhancing an immune response in a mammal.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 29, 2022
    Assignee: THE GOVERNMENT OF THE UNITED STATES, AS REPRESEN
    Inventors: Sheetij Dutta, Adrian Batchelor, Farhat Khan, Mark Langowski
  • Publication number: 20200368341
    Abstract: The disclosure generally provides recombinant proteins comprising Tobamovirus capsid proteins and an immunogenic epitope of an antigen of interest. The recombinant protein can be used to assemble an array comprising a plurality of associated recombinant proteins that can enhance the immunogenicity of the epitope and induce and/or enhance an immune response to the antigen. The disclosure also provides compositions, such as vaccines, that include the recombinant protein as well as methods for inducing and/or enhancing an immune response in a mammal.
    Type: Application
    Filed: September 21, 2018
    Publication date: November 26, 2020
    Inventors: Sheetij Dutta, Adrian Batchelor, Farhat Khan, Mark Langowski
  • Patent number: 10357554
    Abstract: Disclosed are AMA-1 immunogenic peptides and epitopes, nucleotide sequences encoding the peptides and epitopes, compositions, and vaccines including the peptides and/or epitopes. Antibodies that specifically bind to AMA-1 and the AMA-1 epitopes and immunogenic peptides disclosed herein are also provided. The disclosure provides for expression vectors, host cells, and methods for making the polypeptides and antibodies. Also provided are methods of treatment, prevention, vaccination, and/or immunization of a subject against malaria and the clinical indications associated with malaria.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 23, 2019
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventors: Sheetij Dutta, Adrian Batchelor, Michael Foley
  • Patent number: 9919040
    Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: March 20, 2018
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventor: Sheetij Dutta
  • Publication number: 20160279221
    Abstract: Disclosed are AMA-1 immunogenic peptides and epitopes, nucleotide sequences encoding the peptides and epitopes, compositions, and vaccines including the peptides and/or epitopes. Antibodies that specifically bind to AMA-1 and the AMA-1 epitopes and immunogenic peptides disclosed herein are also provided. The disclosure provides for expression vectors, host cells, and methods for making the polypeptides and antibodies. Also provided are methods of treatment, prevention, vaccination, and/or immunization of a subject against malaria and the clinical indications associated with malaria.
    Type: Application
    Filed: November 11, 2014
    Publication date: September 29, 2016
    Inventors: Sheetij Dutta, John David Haynes, Adrian Batchelor, Michael Foley
  • Publication number: 20160038580
    Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
    Type: Application
    Filed: July 14, 2015
    Publication date: February 11, 2016
    Inventor: Sheetij Dutta
  • Patent number: 9115205
    Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: August 25, 2015
    Assignee: The United States of America, as represented by the Secretary of the Army
    Inventor: Sheetij Dutta
  • Publication number: 20130259890
    Abstract: The present invention provides novel nucleotide sequence and other constructs used for expression of novel recombinant P. falciparum circumsporozoite proteins in bacterial cells such as E. coli. Processes are provided for producing a soluble recombinant P. falciparum CSP from E. coli. Methods to produce a human-grade, highly immunogenic anti-malaria vaccine based on CSP are shown. The novel recombinant P. falciparum circumsporozoite protein by itself or in combination with other malaria antigens or adjuvants can form the basis of an effective malaria vaccine.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 3, 2013
    Inventor: Sheetij Dutta
  • Patent number: 7150875
    Abstract: In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: December 19, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware
  • Publication number: 20060264619
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
    Type: Application
    Filed: January 13, 2006
    Publication date: November 23, 2006
    Inventors: David Lanar, Sheetij Dutta, Lisa Ware, Lalitha Nair
  • Patent number: 7060276
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: June 13, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
  • Patent number: 7029685
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: April 18, 2006
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P. V. Nair
  • Publication number: 20050009057
    Abstract: In this application is described a method for determining the presence or absence of functional anti-AMA-1 invasion-inhibitory antibodies in a sample. This method can serve as a correlate for immunity of a P. falciparum AMA-1-based vaccine or as a correlate for immunity to P. falciparum by natural exposure if that immunity was induced by invasion inhibitory antibodies against the AMA-1 protein.
    Type: Application
    Filed: May 5, 2004
    Publication date: January 13, 2005
    Inventors: Sheetij Dutta, David Lanar, John Hannes
  • Publication number: 20030157650
    Abstract: In this application is the expression and purification of a recombinant Plasmodium vivax (SalI) PvMSP-1 p42. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant PvMSP-1 p42 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: March 18, 2002
    Publication date: August 21, 2003
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware
  • Publication number: 20030138450
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a protein for use alone, or as part of, a vaccine to prevent malaria.
    Type: Application
    Filed: October 15, 2002
    Publication date: July 24, 2003
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P.V. Nair
  • Publication number: 20030032787
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) AMA-1 ectodomain. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant AMA-1 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: March 25, 2002
    Publication date: February 13, 2003
    Inventors: David E. Lanar, Sheetij Dutta, Lisa A. Ware, Lalitha P.V. Nair